Authors

Latest:

Dr. Lynch on the Immuno-Oncology Network at Bristol-Myers Squibb

Thomas Lynch, Jr, MD, Vice President and Chief Scientific Officer at Bristol-Myers Squibb, discusses the Immuno-Oncology (IO) Network at Bristol-Myers Squibb.

Thomas M. Churilla, MD

Latest:

Dr. Churilla on Impact of Health Insurance Status on Patients With HNSCC

Thomas M. Churilla, MD, Department of Radiation Oncology, Fox Chase Cancer Center, discusses a study exploring the impact of health insurance status on the presentation, local management, and outcomes of patients with head and neck cancer.

Thomas Marron, MD, PhD

Latest:

Dr Marron on the Evolving Role of Tarlatamab in SCLC

Thomas Marron, MD, PhD, discusses how findings from the DeLLphi-303 trial are shaping the use of tarlatamab across treatment settings in small cell lung cancer.

Thomas Martin, MD, UCSF Helen Diller Family

Thomas Martin, MD, UCSF Helen Diller Family Comprehensive Cancer Center

Latest:

Isatuximab, Bortezomib, Lenalidomide, and Dexamethasone (Isa-VRd) in Newly Diagnosed Multiple Myeloma (NDMM): Outcomes in Patients with 1q21⁺ Status in the Phase 3 IMROZ Study

Presented by Dr. Thomas Martin, this IMROZ subgroup analysis demonstrated that adding isatuximab to standard VRd therapy improved progression-free survival and deepened responses in transplant-ineligible patients with newly diagnosed multiple myeloma and 1q21+ status, a high-risk cytogenetic subgroup.

Thomas Powles MBBS, MRCP, MD

Thomas Powles, MBBS, MRCP, MD, is a professor of genitourinary oncology and the director of the Barts Cancer Centre at St. Bartholomew’s Hospital in London, England.

Latest:

IMvigor011: A Phase 3 Trial of Circulating Tumour (ct)DNA-Guided Adjuvant Atezolizumab vs Placebo in Muscle-Invasive Bladder Cancer

Thomas Powles, MBBS, MRCP, MD discusses IMvigor011: a Phase 3 trial of circulating tumour (ct)DNA-guided adjuvant atezolizumab vs placebo in muscle-invasive bladder cancer.

Thomas Powles, MD

Latest:

Challenges in Standardizing ctDNA-guided MRD Testing in MIBC

Explore the challenges and advancements in ctDNA-based testing for cancer care, focusing on personalized approaches and sensitivity in diverse tumor types.

Thomas Powles, MD, MBBS, MRCP

Latest:

Dr Powles on Results from a Q-TWiST Analysis of Belzutifan vs Everolimus in Previously Treated Advanced RCC

Thomas Powles, MD, discusses results from a Q-TWiST analysis of belzutifan vs everolimus in previously treated advanced renal cell carcinoma.

Thomas Prebet, MD, PhD.

Thomas Prebet, MD, PhD, Yale Cancer Center

Thomas R. Barr, MBA

Latest:

Performance Metrics in Oncology

In 2011, the Medicare Electronic Health Record Incentive Program began paying physicians and hospitals for the measurement and reporting of performance metrics through the utilization of certified electronic medical record software.

Thomas R. McLean

Latest:

Metadata: An Orwellian Big Brother within Electronic Medical Records

Consider this hypothetical situation: A patient with new onset of a major depression is evaluated by a physician who has found no evidence of suicidal ideation.

Thomas S. Uldrick, MD

Latest:

Dr. Uldrick on Rituximab Plus Liposomal Doxorubicin in HIV-Infected Patients With KSHV-MCD

Thomas S. Uldrick, MD, staff clinician, HIV and AIDS Malignancy Branch, Center for Cancer Research at the National Institutes of Health, discusses long-term data from a study examining rituximab plus liposomal doxorubicin in HIV-infected patients with Kaposi sarcoma (KS) herpes virus-associated multicentric Castleman disease.

Thomas Seufferlein, MD, University of Ulm

Thomas W. Dubensky, PhD

Latest:

Thomas Dubensky on How ADU-S100 Activates STING

Thomas W. Dubensky Jr, PhD, chief scientific officer, Aduro Biotech, discusses a study of ADU-S100 and how it activates the human STING receptor, which is found to have presence in multiple tumor types.

Thomas W. Flaig, MD

Latest:

Dr. Flaig on Immune Checkpoint Inhibitors in Advanced Bladder Cancer

Thomas W. Flaig, MD, discusses the utility of immune checkpoint inhibitors in advanced bladder cancer.

Thomas W. LeBlanc, MD

Latest:

Dr. LeBlanc Discusses End-of-Life Care for Hematologic Malignancies

Thomas W. LeBlanc, MD, MA, medical oncologist, palliative care physician, Duke Cancer Institute, discusses end-of-life care for patients with hematologic malignancies.

Thomas Wright, MD

Latest:

HPV Test With Genotyping Tops Cervical Cancer Screening Strategies

Cervical cancer screening based on identification of human papillomavirus (HPV) strains outperformed primary liquid cytology for detection of high-grade cervical intraepithelial neoplasia (CIN), data from a large cohort study showed.

Tian Zhang, MD, MHS, UT Southwestern Medical Center

Latest:

Dr Zhang on Topics of Ongoing Debate Within Prostate Cancer

Tian Zhang, MD, MHS, discusses areas of ongoing debate regarding prostate cancer management.

Tian Zhang, MD, Duke Cancer Center

Latest:

Series Wrap-up: Novel Therapies for mRCC

A panel of expert oncologists who manage patients with renal cell carcinoma share enthusiasm over the use of newer novel-based treatment approaches for metastatic disease.